Stocks making the biggest moves midday: Oracle, Everpure, Meta Platforms, Nebius, Bloom Energy, MGM & more

Midday trading was marked by sharp, company-specific moves: MGM Resorts fell 10% after Barry Diller's People withdrew its acquisition proposal, while Everpure surged 18% after forecasting fiscal 2028 revenue of $7.0B-$7.3B versus $6.19B consensus. Oracle declined 4% following its force-majeure notice on the New Mexico data-center project, pulling contracted fuel-cell supplier Bloom Energy down nearly 6%; semiconductor shares also weakened, with SMH off more than 1%. Upside movers included Nebius, up over 6% after Bank of America raised 2026-28 revenue expectations, and GoDaddy, up roughly 3% on reports of a takeover offer from Gen Digital.

Analysis

The New Mexico disruption matters less as an isolated ORCL construction issue than as a test of AI infrastructure economics: power delivery, not GPU availability, is becoming the binding constraint. BE carries concentrated execution and financing risk because its valuation embeds conversion of large, multi-year data-center awards into deployed capacity; any delay shifts revenue recognition while fixed manufacturing and working-capital needs remain. Over the next 1-3 months, ORCL disclosures on alternate power arrangements, project milestones, and customer commitments will determine whether this is a contained contract dispute or evidence that incremental AI capex faces lower returns and longer build cycles.

NBIS is positioned at the opposite end of the risk spectrum: long-duration contracted utilization can support capacity financing, but its equity outcome is highly sensitive to the spread between dedicated hyperscale pricing and shorter-duration AI compute pricing. The key non-consensus risk is that the high-rate capacity tranche is cyclical and could compress sharply if NVDA-based supply comes online faster than enterprise workloads scale. A sustained re-rating requires evidence that signed backlog, not analyst-model assumptions, supports 2027-28 utilization and that capex can be funded without material dilution.

The GDDY situation creates a cleaner event-driven setup than the broader AI complex. GEN has strategic logic in adding recurring small-business subscriptions and customer acquisition channels, but the market should discount a bidder materially if financing, leverage, or antitrust scrutiny requires a higher premium; GDDY shareholders retain upside only while a credible formal offer emerges. MGM's failed-bid selloff may be technically exaggerated, yet the withdrawal removes the near-term valuation floor and refocuses investors on organic Las Vegas demand, digital investment returns, and leverage reduction over the next two quarters.

CRL's guidance posture is incrementally constructive because upper-end delivery would signal stabilization in biotech outsourcing demand, but the stock needs order/backlog conversion rather than another reaffirmation to sustain multiple expansion. In gold equities, a short-term bullion drawdown can create selective entry points only if real-rate and dollar moves stabilize; higher-beta operators such as KGC and IMG should continue to underperform NEM in any further metal-price correction.

Key Decisions for Investors

• Avoid or maintain a tactical short in BE versus long ETN over the next 1-3 months: BE is exposed to project timing, customer concentration, and funding needs, while ETN benefits from data-center electrical buildout across a broader customer base. Cover if ORCL confirms binding alternative-power procurement and an unchanged deployment timetable.
• Use ORCL weakness as a watch, not a buy, until the next project update: initiate only after evidence that the affected build remains within capex and schedule parameters. A further delay that pushes cloud capacity availability beyond one quarter would justify lower cloud revenue estimates and a short versus MSFT.
• Event-driven pair: long GDDY / short GEN in modest size while takeover optionality remains live, with a 30-60 day review window. Exit the pair if no formal proposal or financing evidence appears; GEN downside is likely larger if it must raise consideration or abandon the pursuit, while GDDY can retrace sharply on deal failure.
• Accumulate CRL only on confirmation of quarterly book-to-bill improvement and maintained full-year margin guidance; target a 6-12 month recovery trade versus IBB. Falsify on renewed biotech-client cancellation commentary or a reduction in the upper-end earnings outlook.
• For gold exposure, prefer NEM over KGC/IMG on a 6-18 month horizon; do not add before gold stabilizes and real yields stop rising. A sustained break below the recent bullion support level would favor reducing all miner beta rather than averaging down.